1. Home
  2. PDC vs MRKR Comparison

PDC vs MRKR Comparison

Compare PDC & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PDC

Perpetuals.com Ltd American Depositary Shares

N/A

Current Price

$5.10

Market Cap

19.7M

Sector

Technology

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.47

Market Cap

22.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDC
MRKR
Founded
2018
1999
Country
Japan
United States
Employees
20
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.7M
22.5M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
PDC
MRKR
Price
$5.10
$1.47
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
94.3K
55.1K
Earning Date
07-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.46
$0.81
52 Week High
$8.40
$4.07

Technical Indicators

Market Signals
Indicator
PDC
MRKR
Relative Strength Index (RSI) 53.13 58.43
Support Level $5.92 $1.35
Resistance Level $7.90 $1.52
Average True Range (ATR) 0.68 0.06
MACD 0.06 0.01
Stochastic Oscillator 95.24 92.95

Price Performance

Historical Comparison
PDC
MRKR

About PDC Perpetuals.com Ltd American Depositary Shares

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: